JordanBerlinMD

Clinical Trials

• Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Start of enrollment: 2017 Aug 23

  Active, not recruiting

  Phase 1, Phase 2

• Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery Start of enrollment: 2005 May 01

  Completed

  Phase 2

• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer Start of enrollment: 2011 Jun 01

  Terminated

  Phase 2

• Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2008 Oct 01

  Completed

  Phase 2

• Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies Start of enrollment: 2016 Nov 01

  Terminated

  Phase 1, Phase 2

• Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2015 Apr 01

  Unknown status

  Phase 2

• Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16

  Completed

  Phase 1

• A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Start of enrollment: 2022 Feb 23

  Terminated

  Phase 1

  Roles: Contact

• Join now to see all